These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 16540630)

  • 1. Aluminum toxicity due to intravenous injection of boiled methadone.
    Yong RL; Holmes DT; Sreenivasan GM
    N Engl J Med; 2006 Mar; 354(11):1210-1. PubMed ID: 16540630
    [No Abstract]   [Full Text] [Related]  

  • 2. Aluminum toxicity following IV use of oral methadone solution.
    Friesen MS; Purssell RA; Gair RD
    Clin Toxicol (Phila); 2006; 44(3):307-14. PubMed ID: 16749550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs.
    Yokel RA; Ackrill P; Burgess E; Day JP; Domingo JL; Flaten TP; Savory J
    J Toxicol Environ Health; 1996 Aug; 48(6):667-83. PubMed ID: 8772805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aluminum and deferoxamine kinetics in CAPD.
    Mactier RA
    Adv Perit Dial; 1991; 7():26-9. PubMed ID: 1680440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aluminum accumulation and deferoxamine].
    Ritz E
    Dtsch Med Wochenschr; 1993 Jul; 118(26):998-9. PubMed ID: 8519236
    [No Abstract]   [Full Text] [Related]  

  • 6. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic aluminum poisoning in continuous ambulatory peritoneal dialysis: treatment with deferoxamine].
    Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK
    Dtsch Med Wochenschr; 1989 Feb; 114(7):253-7. PubMed ID: 2917487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron and aluminum in Alzheimer's disease.
    Di Lorenzo F; Di Lorenzo B
    Neuro Endocrinol Lett; 2013; 34(6):504-7. PubMed ID: 24378455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Speech apraxia in dialysis-associated aluminum encephalopathy].
    Haug BA; Botsch G; Felgenhauer K
    Nervenarzt; 1991 Oct; 62(10):637-40. PubMed ID: 1749454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine.
    Min DI; D'Elia JA
    Clin Pharm; 1992 Jul; 11(7):636-9. PubMed ID: 1617916
    [No Abstract]   [Full Text] [Related]  

  • 11. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
    Abreo K; Brown ST; Sella M; Trapp G
    J Lab Clin Med; 1989 Jan; 113(1):50-7. PubMed ID: 2909650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrafiltration studies in vitro of serum aluminum in dialysis patients after deferoxamine chelation therapy.
    Leung FY; Hodsman AB; Muirhead N; Henderson AR
    Clin Chem; 1985 Jan; 31(1):20-3. PubMed ID: 3965214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Desferal treatment of aluminum poisoning; effect on serum concentrations of aluminum (Al), iron (Fe) and copper (Cu)].
    Günther K; Winnefeld K; Stein G; Sperschneider H; Schröter H; Fünfstück R
    Z Urol Nephrol; 1986 Oct; 79(10):569-76. PubMed ID: 3811645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and histological results of long-term management of aluminium overloading in uraemic patients with desferrioxamine.
    Canavese C; Pacitti A; Segoloni G; Thea A; D'Amicone M; Stratta P; Rossi P; Sabbioni E; Pietra R; Constantini S
    J Trace Elem Electrolytes Health Dis; 1989 Mar; 3(1):17-23. PubMed ID: 2535315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease.
    Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; van Hooff I; Dratwa M; Verbeelen D
    Clin Nephrol; 1985 Nov; 24(5):237-41. PubMed ID: 4075595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute iron intoxication: change in urine color during chelation therapy with deferoxamine.
    Fernández S; Castro P; Nogué S; Nicolás JM
    Intensive Care Med; 2014 Jan; 40(1):104. PubMed ID: 24072332
    [No Abstract]   [Full Text] [Related]  

  • 18. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine.
    Warady BA; Ford DM; Gaston CE; Sedman AB; Huffer WE; Lum GM
    Pediatrics; 1986 Oct; 78(4):651-5. PubMed ID: 3763276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 3-hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of aluminum intoxication than does desferrioxamine.
    Yokel RA; Meurer KA; Skinner TL; Fredenburg AM
    Drug Metab Dispos; 1996 Jan; 24(1):105-11. PubMed ID: 8825197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The causes of aluminum cumulation and poisoning in patients with chronic kidney failure treated by hemodialysis on a regular program and the possibilities for therapy].
    Válek A; Sulková S; Laurinová Z
    Ter Arkh; 1991; 63(6):89-93. PubMed ID: 1948757
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.